111 related articles for article (PubMed ID: 9118461)
1. Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan.
Rosing H; Herben VM; van Gortel-van Zomeren DM; Hop E; Kettenes-van den Bosch JJ; ten Bokkel Huinink WW; Beijnen JH
Cancer Chemother Pharmacol; 1997; 39(6):498-504. PubMed ID: 9118461
[TBL] [Abstract][Full Text] [Related]
2. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.
Rosing H; Doyle E; Davies BE; Beijnen JH
J Chromatogr B Biomed Appl; 1995 Jun; 668(1):107-15. PubMed ID: 7550966
[TBL] [Abstract][Full Text] [Related]
3. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.
Rosing H; van Zomeren DM; Doyle E; Bult A; Beijnen JH
Anticancer Drugs; 1998 Aug; 9(7):587-92. PubMed ID: 9773801
[TBL] [Abstract][Full Text] [Related]
4. Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.
Rosing H; van Zomeren DM; Doyle E; ten Bokkel WW; Schellens JH; Bult A; Beijnen JH
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):191-203. PubMed ID: 10360438
[TBL] [Abstract][Full Text] [Related]
5. Determination of plasma topotecan and its metabolite N-desmethyl topotecan as both lactone and total form by reversed-phase liquid chromatography with fluorescence detection.
Bai F; Kirstein MN; Hanna SK; Iacono LC; Johnston B; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Feb; 784(2):225-32. PubMed ID: 12505770
[TBL] [Abstract][Full Text] [Related]
6. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine.
Loos WJ; Stoter G; Verweij J; Schellens JH
J Chromatogr B Biomed Appl; 1996 Apr; 678(2):309-15. PubMed ID: 8738036
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
van Warmerdam LJ; Verweij J; Schellens JH; Rosing H; Davies BE; de Boer-Dennert M; Maes RA; Beijnen JH
Cancer Chemother Pharmacol; 1995; 35(3):237-45. PubMed ID: 7805183
[TBL] [Abstract][Full Text] [Related]
8. The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma.
Rosing H; Doyle E; Beijnen JH
J Pharm Biomed Anal; 1996 Nov; 15(2):279-86. PubMed ID: 8933430
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of topotecan.
Herben VM; ten Bokkel Huinink WW; Beijnen JH
Clin Pharmacokinet; 1996 Aug; 31(2):85-102. PubMed ID: 8853931
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity.
Stewart CF; Baker SD; Heideman RL; Jones D; Crom WR; Pratt CB
J Clin Oncol; 1994 Sep; 12(9):1946-54. PubMed ID: 8083716
[TBL] [Abstract][Full Text] [Related]
11. Determination of total and lactone form of a new camptothecin derivative gimatecan (ST1481) and its metabolite ST1698 in human plasma by high-performance liquid chromatography with fluorimetric detection.
Pace S; Capocasa F; Tallarico C; Frapolli R; Zucchetti M; Longo A
J Pharm Biomed Anal; 2009 Oct; 50(3):507-14. PubMed ID: 19553057
[TBL] [Abstract][Full Text] [Related]
12. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma.
Beijnen JH; Smith BR; Keijer WJ; van Gijn R; ten Bokkel Huinink WW; Vlasveld LT; Rodenhuis S; Underberg WJ
J Pharm Biomed Anal; 1990; 8(8-12):789-94. PubMed ID: 2100624
[TBL] [Abstract][Full Text] [Related]
13. Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.
Oguma T; Konno T; Inaba A; Nakaoka M
Biomed Chromatogr; 2001 Apr; 15(2):108-15. PubMed ID: 11268051
[TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatographic analysis of the investigational anticancer drug 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro-volumes of human plasma.
van Gijn R; Herben VM; Hillebrand MJ; ten Bokkel Huinink WW; Bult A; Beijnen JH
J Pharm Biomed Anal; 1998 Sep; 17(8):1257-65. PubMed ID: 9800645
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.
Baker SD; Heideman RL; Crom WR; Kuttesch JF; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 1996; 37(3):195-202. PubMed ID: 8529278
[TBL] [Abstract][Full Text] [Related]
16. An overview of the clinical pharmacology of topotecan.
Dennis MJ; Beijnen JH; Grochow LB; van Warmerdam LJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-12-S5-18. PubMed ID: 9122737
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
van Warmerdam LJ; Creemers GJ; Rodenhuis S; Rosing H; de Boer-Dennert M; Schellens JH; ten Bokkel Huinink WW; Davies BE; Maes RA; Verweij J; Beijnen JH
Cancer Chemother Pharmacol; 1996; 38(3):254-60. PubMed ID: 8646800
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: application to camptothecin derivatives.
Gravel E; Bourget P; Mercier L; Paci A
J Pharm Biomed Anal; 2005 Sep; 39(3-4):581-6. PubMed ID: 16023817
[TBL] [Abstract][Full Text] [Related]
19. Reduced albumin binding promotes the stability and activity of topotecan in human blood.
Mi Z; Malak H; Burke TG
Biochemistry; 1995 Oct; 34(42):13722-8. PubMed ID: 7577964
[TBL] [Abstract][Full Text] [Related]
20. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
Zamboni WC; Gajjar AJ; Heideman RL; Beijnen JH; Rosing H; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Mar; 4(3):783-9. PubMed ID: 9533548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
